<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
[x] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the quarterly period ended September 30, 2000
or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the Transition Period From _ to _
Commission file number 0-30318
VENTIV HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware 52-2181734
(State or other jurisdiction (IRS Employer
of incorporation or organization) Identification No.)
1114 Avenue of the Americas, New York, New York 10036
(Address of principal executive office and zip code)
(212) 768-8000
(Registrant's telephone number, including area code)
Indicate by check mark whether registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [x]* No [ ]
*Based upon satisfaction of the conditions set forth in Staff Legal Bulletin
No. 4
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Common Stock, par value $0.001, 22,805,511 shares outstanding as of November
1, 2000
<PAGE>
VENTIV HEALTH, INC.
FORM 10-Q
INDEX
<TABLE>
<CAPTION>
Page
------
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
<S> <C>
Condensed Consolidated Balance Sheets as of September 30, 2000 (unaudited) and
December 31, 1999 ........................................................................ 1
Condensed Consolidated Statements of Operations for the three- and nine-month periods ended
September 30, 2000 and 1999 (unaudited) .................................................. 2
Condensed Consolidated Statements of Cash Flows for the nine-month periods ended
September 30, 2000 and 1999 (unaudited) .................................................. 3
Notes to Condensed Consolidated Financial Statements ...................................... 4-7
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ... 8-16
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk .............................. 16
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings ....................................................................... 17
ITEM 4. Submission of Matters to a Vote of Security Holders ..................................... 17
ITEM 6. Exhibits and Reports on Form 8-K ........................................................ 17
SIGNATURES ....................................................................................... 18
</TABLE>
<PAGE>
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
VENTIV HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
<TABLE>
<CAPTION>
September 30, December 31,
------------- ------------
2000 1999
------------- ------------
(unaudited)
ASSETS
Current assets:
<S> <C> <C>
Cash and equivalents ........................................................................ $ 26,657 $ 37,627
Marketable securities ....................................................................... -- 1,898
Accounts receivable, net of allowances for doubtful accounts of $1,854 and $2,517 at
September 30, 2000 and December 31, 1999, respectively ..................................... 53,261 51,158
Unbilled services ........................................................................... 17,924 13,430
Other current assets ........................................................................ 9,788 7,568
--------- ---------
Total current assets ..................................................................... 107,630 111,681
Property and equipment, net .................................................................. 30,883 14,742
Goodwill and other intangible assets, net .................................................... 91,130 95,816
Deferred tax assets .......................................................................... 9,101 9,732
Investments and other noncurrent assets ...................................................... 2,977 1,293
--------- ---------
Total assets ............................................................................. $ 241,721 $ 233,264
========= =========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Lines of credit ............................................................................. $ 3,010 $ 36
Current maturities of long-term debt ........................................................ 55 55
Accrued payroll ............................................................................. 22,756 18,082
Accounts payable ............................................................................ 5,523 8,801
Accrued expenses ............................................................................ 19,161 26,971
Client advances ............................................................................. 3,842 4,346
Unearned revenue ............................................................................ 16,500 28,060
--------- ---------
Total current liabilities ................................................................ 70,847 86,351
Long-term debt ............................................................................... 16,281 1,155
Other liabilities ............................................................................ 15,635 5
Commitments and contingencies ................................................................ -- --
Stockholders' Equity:
Preferred stock, $.001 par value, 10,000,000 shares authorized, none issued and outstanding at
September 30, 2000, and December 31, 1999 ................................................... -- --
Common stock, $.001 par value, 50,000,000 shares authorized; 22,794,712 shares and
25,231,215 shares issued and outstanding at September 30, 2000 and December 31, 1999,
respectively ................................................................................ 23 25
Additional paid-in-capital ................................................................... 156,080 176,495
Deferred compensation ........................................................................ (3,301) (4,219)
Treasury stock, at cost, 494,000 shares at December 31, 1999 ................................. -- (4,307)
Accumulated other comprehensive losses ....................................................... (3,843) (2,401)
Retained deficit ............................................................................. (10,001) (19,840)
--------- ---------
Total stockholders' equity ............................................................... 138,958 145,753
--------- ---------
Total liabilities and stockholders' equity ............................................... $ 241,721 $ 233,264
========= =========
</TABLE>
See accompanying notes to condensed consolidated financial statements.
- 1 -
<PAGE>
VENTIV HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
<TABLE>
<CAPTION>
For the Three Months For the Nine Months
-------------------- --------------------
Ended September 30, Ended September 30,
---------------------- ---------------------
2000 1999 2000 1999
-------- -------- -------- --------
(unaudited)
-----------
<S> <C> <C> <C> <C>
Revenues ..................................... $ 103,355 $ 72,900 $ 301,257 $ 254,159
Operating expenses:
Costs of services .......................... 85,366 71,895 246,741 210,040
Selling, general and administrative expenses 10,792 13,138 35,589 33,606
Recapitalization costs ..................... -- 2,100 -- 2,100
Acquisition and related costs .............. -- 5,741 -- 5,741
Restructuring costs ........................ 2,000 -- 2,000 1,694
--------- --------- --------- ---------
Operating income (loss) ...................... 5,197 (19,974) 16,927 978
Interest expense ............................. (514) (56) (1,565) (179)
Investment income ............................ 248 121 1,033 494
--------- --------- --------- ---------
Earnings (losses) before income taxes ........ 4,931 (19,909) 16,395 1,293
Provision for (benefit from) income taxes .... 1,972 (6,928) 6,558 1,635
--------- --------- --------- ---------
Net earnings (losses) ...................... $ 2,959 $ (12,981) $ 9,837 $ (342)
========= ========= ========= =========
Earnings (losses) per share (see Note 4):
Basic ...................................... $ 0.13 $ (0.55) $ 0.43 $ (0.01)
Diluted .................................... $ 0.13 $ (0.55) $ 0.42 $ (0.01)
</TABLE>
See accompanying notes to condensed consolidated financial statements.
- 2 -
<PAGE>
VENTIV HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
<TABLE>
<CAPTION>
For the Nine Months
------------------------
Ended September 30,
------------------------
2000 1999
-------- --------
(unaudited)
Cash flows from operating activities:
<S> <C> <C>
Net earnings (losses) ............................................ $ 9,837 $ (342)
Adjustments to reconcile net earnings (losses) to net cash used in
operating activities:
Depreciation and amortization ................................... 9,152 5,831
Deferred taxes .................................................. (97) (843)
Losses on disposals of assets ................................... 539 951
Non-cash expense for stock issuance ............................. -- 5,741
Non-cash expense for restricted stock vesting ................... 818 2,100
Net changes in assets and liabilities:
Accounts receivable, net ........................................ (2,103) 246
Unbilled services ............................................... (4,494) (1,841)
Deposits and other noncurrent assets ............................ (1,492) 3,295
Accrued payroll, accounts payable and accrued expenses .......... (6,414) (20,789)
Client advances and unearned revenue ............................ (12,064) 1,492
Other ........................................................... 344 2,967
-------- --------
Net cash used in operating activities ............................ (5,974) (1,192)
Cash flows from investing activities:
Cash on hand at acquired businesses ............................. -- 2,917
Purchase of subsidiaries ........................................ -- (1,135)
Investment in Rxcentric.com, Inc. ............................... (2,000) --
Purchase of license agreements .................................. -- (628)
Proceeds from sale of fixed assets .............................. 94 --
Proceeds from sale of marketable securities ..................... 1,903 --
Purchases of property and equipment ............................. (5,816) (6,729)
-------- --------
Net cash used in investing activities ............................ (5,819) (5,575)
Cash flows from financing activities:
Net borrowings (repayment) of line of credit .................... 18,100 (1,807)
Payment of capital lease obligations ............................ (1,685) --
Purchases of treasury shares .................................... (17,455) --
Investments and advances from Snyder ............................ -- 22,636
Proceeds from the exercise of stock options ..................... 1,252 --
Other ........................................................... -- (500)
-------- --------
Net cash provided by financing activities ........................ 212 20,329
-------- --------
Effect of exchange rate changes on cash and equivalents ........... 611 (1,430)
-------- --------
Net increase (decrease) in cash and equivalents ................... (10,970) 12,132
Cash and equivalents, beginning of period ......................... 37,627 25,664
-------- --------
Cash and equivalents, end of period ............................... $ 26,657 $ 37,796
======== ========
Supplemental disclosures of cash flow information:
Cash paid for interest .......................................... $ 986 $ 282
Cash paid for income taxes ...................................... $ 9,765 $ 10,148
Supplemental disclosures of non-cash activities:
Businesses acquired with Snyder stock ........................... $ -- $ 16,336
</TABLE>
See accompanying notes to condensed consolidated financial statements.
- 3 -
<PAGE>
VENTIV HEALTH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
1. Organization, Business and Basis of Presentation:
Organization
Snyder Communications, Inc. ("Snyder"), a Delaware corporation, completed an
initial public offering of its common stock on September 24, 1996. Snyder
created the business currently conducted by the registrant, Ventiv Health, Inc.
("Ventiv"), in 1997 as a result of a merger transaction with a U.S. provider of
pharmaceutical sales and marketing services. After forming its pharmaceutical
sales and marketing services business segment in 1997, Snyder completed a series
of acquisitions that expanded the magnitude, scope of services and geographic
presence of this business.
On June 22, 1999, the Board of Directors of Snyder approved a plan to effect
the distribution (the "Distribution") of Snyder's healthcare marketing assets of
its healthcare marketing services business in the third quarter of 1999 to a
newly formed subsidiary, Ventiv Health, Inc. Snyder consummated the Distribution
on September 27, 1999 through a special dividend of one share of common stock of
Ventiv Health, Inc. for every three shares of Snyder common stock. As a result
of the Distribution, Ventiv became an independent, publicly traded corporation
[NASDAQ: VTIV].
Business
Ventiv Health, Inc. is a unique sales and marketing partner providing
innovative strategic and tactical solutions globally for the pharmaceutical and
life sciences industry. The Company offers a broad range of integrated sales and
marketing services including: specially designed strategic marketing plans,
educational programs targeted to physicians, sales execution, and consulting and
analytics. Clients include many of the leading pharmaceutical and life sciences
companies, including: Aventis, Bausch & Lomb, Baxter, Bayer, Bristol-Myers
Squibb, Eli Lilly, Endo Pharmaceuticals, Glaxo Wellcome, Johnson & Johnson,
Merck, Novartis, Pfizer and Pharmacia. Ventiv Health operates across the United
States, France, Germany, United Kingdom, Austria and Hungary.
Basis of Presentation
The operations of Ventiv Health, Inc. consist principally of the healthcare
sales, healthcare market research and strategic planning, and healthcare
educational communications services formerly conducted by the healthcare
marketing services segment of Snyder.
The unaudited condensed consolidated financial statements present the
financial position, results of operations and cash flows of Snyder's healthcare
marketing services business, referred to herein as "Ventiv", "Ventiv Health" or
the "Company", as if it were operated as a stand-alone entity apart from Snyder
for all periods prior to the Distribution. Snyder's historical basis in the
assets and liabilities contributed to Ventiv in the Distribution has been
carried over and appropriately reflected in these condensed consolidated
financial statements. All expenses reflected in the condensed consolidated
financial statements for periods prior to the Distribution are costs
specifically identified to the Company. It is not practicable to estimate costs
that would have been incurred by the Company if it had been operated on a stand-
alone basis prior to the Distribution.
- 4 -
<PAGE>
VENTIV HEALTH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
The accompanying unaudited condensed consolidated financial statements have
been prepared pursuant to the interim rules and regulations of the Securities
and Exchange Commission. As a result, certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles ("GAAP") have been omitted. The
Company believes that the disclosures made are adequate such that the
information presented is not misleading. The condensed consolidated financial
statements reflect all adjustments (consisting of only normal recurring
adjustments) which, in the opinion of management, are necessary to present
fairly the financial position, results of operations and cash flows of the
Company as of September 30, 2000. Operating results for the three- and nine-
month periods ended September 30, 2000 are not necessarily indicative of the
results that may be expected for the year ending December 31, 2000. The
condensed consolidated financial statements should be read in conjunction with
the consolidated financial statements and accompanying notes included in the
Company's Annual Report on Form 10-K for the year ended December 31, 1999, filed
with the Securities and Exchange Commission on March 30, 2000.
2. Strategic Business Alliances and Related Transactions
On March 10, 2000, Ventiv entered into an exclusive strategic alliance with
RxCentric.com, Inc. ("RxCentric"), a privately held New York, NY-based company
which provides physicians with rapid access to comprehensive drug and
pharmaceutical-related information via the Internet. Pursuant to a multi-year
agreement, the companies will share in the revenues generated from this
alliance, subject to significant revenue and physician recruitment milestones.
In connection with this strategic alliance, Ventiv has invested $2 million in
RxCentric in exchange for a minority equity position in the firm, which is being
accounted for under the cost method.
Following this transaction, the Company announced the formation of a new
operating unit, e-Ventiv, which will focus on the development of Internet-based
solutions that complement Ventiv's existing sales, communications and strategic
consulting businesses, enhancing the Company's ability to provide superior
outsourced marketing and sales solutions. Specifically, e-Ventiv will focus on
the design and development of solutions oriented toward physician interaction (a
primary objective of the alliance with RxCentric), patient interaction (a
primary objective of the alliance with HeliosHealth.com--see below) and value-
added information for pharmaceutical clients.
On October 12, 2000, Ventiv entered into a strategic alliance with
HeliosHealth.com ("Helios"), a unique direct-to-consumer ("DTC") Internet
platform that is the leading provider of interactive kiosks - or "e.stations" -
in physician waiting rooms. Helios has installed over 700 e.stations in large,
high prescribing primary care and OB/GYN group practices, which generate more
than 100,000 unique visits per month. In addition, the website generates an
additional 100,000 unique visits per month. Helios has sold over 15 sponsorships
to major pharma companies including Glaxo Wellcome, Johnson & Johnson, Pfizer,
Pharmacia and SmithKline Beecham. The companies will jointly market targeted
advertising and content to clients and will share revenue generated pursuant to
a multi-year agreement. In addition, Ventiv's Health Products Research division
will continue to integrate DTC into its traditional consulting services and
market research efforts. In connection with this agreement, Ventiv has also made
a minority equity investment in Helios of $0.5 million.
Ventiv does not expect business generated through the alliances with RxCentric
and HeliosHealth.com to materially affect results of operations for the year
ending December 31, 2000.
3. Share Repurchase Program:
On March 15, 2000, the Board of Directors authorized the repurchase of an
additional $12.5 million of the Company's stock, bringing the total authorized
to $37.5 million. The Company has repurchased approximately 1.7 million and 2.2
million shares for approximately $17.4 million and $21.8 million (including
applicable fees and broker commissions) for the nine months ending September 30,
2000 and for the repurchase program from inception to date, respectively.
- 5 -
<PAGE>
VENTIV HEALTH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
4. Earnings Per Share:
The Company has applied Statement of Financial Accounting Standards No. 128,
"Earnings Per Share" ( "SFAS No. 128 ") to all periods presented in these
financial statements. SFAS No. 128 requires disclosure of basic and diluted
earnings per share ( "EPS "). Basic EPS is computed by dividing reported
earnings available to common stockholders by the weighted average number of
shares outstanding without consideration of common stock equivalents or other
potentially dilutive securities. Diluted EPS gives effect to common stock
equivalents and other potentially dilutive securities outstanding during the
period. For periods prior to the Distribution, basic and diluted EPS were
calculated on a pro forma basis using the number of shares of Ventiv common
stock that were issued upon the Distribution. For periods ending subsequent to
the date of the Distribution, the number of shares used to calculate net
earnings per share was based on the actual number of shares of Ventiv common
stock and common stock equivalents outstanding.
The following table presents a reconciliation of the numerators and
denominators of basic and diluted EPS for the three- and nine-month periods
ended September 30, 2000 and pro forma basic and diluted EPS for the three- and
nine-month periods ended September 30, 1999:
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
------------------ -----------------
September 30, 2000 September 30, 2000
------------------ ------------------
2000 1999 2000 1999
------- -------- ------- -------
(in thousands exceptper share data)
Basic EPS Computation
<S> <C> <C> <C> <C>
Net earnings (loss) ......................... $ 2,959 $(12,981) $ 9,837 $ (342)
Weighted average common shares outstanding .. 22,323 23,719 22,692 23,719
------- -------- ------- --------
Basic EPS ................................... $ 0.13 $ (0.55) $ 0.43 $ (0.01)
======= ======== ======= ========
Diluted EPS Computation
Net earnings (loss) ......................... $ 2,959 $(12,981) $ 9,837 $ (342)
Adjustments to net earnings ................. -- -- -- --
------- -------- ------- --------
Net earnings, as adjusted ................... $ 2,959 $(12,981) $ 9,837 $ (342)
Diluted common shares outstanding:
Weighted average common shares outstanding 22,323 23,719 22,692 23,719
Employee stock options ................... 739 n/a 521 n/a
Restricted stock awards .................. 293 n/a 239 n/a
------- -------- ------- --------
Total diluted common shares outstanding .. 23,355 23,719 23,452 23,719
------- -------- ------- --------
Diluted EPS .............................. $ 0.13 $ (0.55) $ 0.42 $ (0.01)
======= ======== ======= ========
</TABLE>
As the Company had a net loss for both the three- and nine-month periods ended
September 30, 1999, the effect of the restricted stock and the outstanding stock
options would have been anti-dilutive. The number of potentially dilutive common
share equivalents for the three- and nine-month periods ending September 30,
1999 were 25,672 and 8,652, respectively.
5. Significant Clients:
During the nine months ended September 30, 2000 and 1999, a single client,
Bristol-Myers Squibb, Inc., accounted for approximately 25% and 10% of the
Company's total revenue, respectively. The Company expects that this client will
continue to provide a significant portion of the Company's revenue for the
remainder of the year.
- 6 -
<PAGE>
VENTIV HEALTH, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS--(Continued)
6. Restructuring Costs:
During the third quarter of 2000, management completed an evaluation of
staffing levels and infrastructure of its European operations. Following this
evaluation, management adopted a restructuring plan which provided for: i)
rationalization of senior and mid-level management in France, the United Kingdom
and Austria (total of 9 employees); ii) early termination of leases in France
and Austria to reduce overall facilities costs and consolidate certain sales
operations, respectively, and; iii) the disposition of assets not associated
with Ventiv's core businesses. The Company will continue to do business in
Austria, but these activities will now be managed by the German operation. In
connection with the adoption of this plan, the Company recorded a pre-tax charge
of $2.0 million. As of September 30, 2000, $1.1 million related to these
restructuring actions was accrued and included in "Accrued expenses" in the
Condensed Consolidated Balance Sheet. The Company expects that the remaining
amounts will be paid out by the end of 2000 or early 2001.
7. Comprehensive Income:
SFAS No. 130, "Reporting Comprehensive Income", was adopted during 1998. This
statement established standards for reporting comprehensive income in financial
statements. Comprehensive income reports the effect on net income of
transactions that are related to equity of the Company, but that have not been
transacted directly with the Company's shareholders. This statement only
modifies disclosures, including financial statement disclosures, and does not
result in other changes to the results or financial position of the Company.
<TABLE>
<CAPTION>
Three Months Ended Nine Months Ended
------------------ ------------------
September 30, 2000 September 30, 2000
------------------ ------------------
2000 1999 2000 1999
------ ------- ------ ------
(in thousands)
<S> <C> <C> <C> <C>
Net earnings (losses) ........................... $2,959 $(12,981) $ 9,837 $ (342)
Other comprehensive earnings (losses), net of tax:
Compensation on shares issued .................. -- (2,100) -- (2,100)
Foreign currency translation adjustment ........ 650 (111) (1,042) (1,269)
------ -------- ------- -------
Comprehensive earnings (losses) ................. $3,609 $(15,192) $ 8,795 $(3,711)
====== ======== ======= =======
</TABLE>
8. Capital Leases:
During the nine-month period ended September 30, 2000, the Company entered
into a master lease agreement to provide a fleet of automobiles for sales
representatives of its US Sales group. Based on the terms of the agreement,
management concluded that the leases were capital in nature based on the
criteria established by Statement of Financial Accounting Standards No. 13 --
"Accounting for Leases". Accordingly, the Company capitalized the leased
vehicles and recorded the related lease obligation of approximately $17.3
million.
- 7 -
<PAGE>
VENTIV HEALTH, INC.
ITEM 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations
On September 27, 1999, Ventiv Health, Inc. ("Ventiv") was spun off from Snyder
Communications, Inc. ("Snyder") in the form of a tax-free dividend to Snyder
stockholders (the "Distribution"). Ventiv is now an independent publicly traded
company [NASDAQ: VTIV]. This Management's Discussion and Analysis of Financial
Condition and Results of Operations covers periods prior to the Distribution,
during which the operations of Ventiv were part of Snyder. The following
information should be read in conjunction with the consolidated financial
statements, accompanying notes and other financial information included in this
Quarterly Report on Form 10-Q and in the Company's most recent Annual Report on
Form 10-K for the year ended December 31, 1999.
Private Securities Litigation Reform Act of 1995--A Caution Concerning Forward-
Looking Statements
Any statement made in this Form 10-Q that deals with information that is not
historical, such as statements concerning our anticipated financial results, are
forward-looking statements. We wish to caution readers not to place undo
reliance on any of these forward-looking statements, which speak only as of the
date made. Such forward-looking statements involve known and unknown risks that
may cause the Company's performance to differ materially from the results
expressed in our periodic reports and registration statements filed with the
Securities and Exchange Commission, our press releases or other public
communications. Such risks include, but are not limited to: changes in trends in
the pharmaceutical industry; uncertainties related to the continued growth of
pharmaceutical outsourcing; our ability to compete successfully with other
services in the market; our ability to maintain large client contracts or to
enter into new contracts; uncertainties related to future incentive payments;
and our ability to operate successfully in new lines of business.
Overview
Ventiv Health, Inc. is a unique sales and marketing partner providing
innovative strategic and tactical solutions globally for the pharmaceutical and
life sciences industry. The Company offers a broad range of integrated sales and
marketing services including: specially designed strategic marketing plans,
educational programs targeted to physicians, sales execution, and consulting and
analytics. Clients include many of the leading pharmaceutical and life sciences
companies, including: Aventis, Bausch & Lomb, Baxter, Bayer, Bristol-Myers
Squibb, Eli Lilly, Endo Pharmaceuticals, Glaxo Wellcome, Johnson & Johnson,
Merck, Novartis, Pfizer and Pharmacia. Ventiv Health operates across the United
States, France, Germany, United Kingdom, Austria and Hungary.
Ventiv's services are designed to develop, execute and monitor strategic
marketing plans for pharmaceutical and other life sciences products and to
conduct educational research and communication services for the medical
community. Snyder created the business currently conducted by Ventiv in January
1997 in a merger transaction with a U.S. provider of pharmaceutical sales and
marketing services. After forming its pharmaceutical sales and marketing service
business segment in 1997, Snyder completed a series of acquisitions that
expanded both the magnitude, scope of services and geographic presence of the
pharmaceutical sales and marketing business, creating the business conducted by
Ventiv today. We plan to focus on internal growth for the foreseeable future as
our primary means of expansion, although we will consider attractive acquisition
opportunities as they arise.
We expect that the complementary services, which Ventiv is able to offer to
its customers as a result of the acquisitions described above, will increase our
opportunities and strengthen our client relationships. We strive to integrate
our service capabilities to provide a coordinated spectrum of healthcare
marketing and sales services. Ventiv's Health Products Research ("HPR") group
designs and monitors product launches and ongoing marketing and sales strategies
with its proprietary programs to maximize resource utilization and return on
investment for pharmaceutical and other life sciences companies. Ventiv Health
Communications provides educational and promotional programs to physicians and
other healthcare professionals. Ventiv Health worldwide sales designs and
executes outsourced sales programs for pharmaceutical and other life sciences
products. Most of Ventiv's largest clients utilize the services of more than one
of our operating groups.
- 8 -
<PAGE>
Strategic Business Alliances and Related Transactions
On March 10, 2000, Ventiv entered into an exclusive strategic alliance with
RxCentric.com, Inc. ("RxCentric"), a privately-held New York, NY-based company
which provides physicians with rapid access to comprehensive drug and
pharmaceutical-related information via the Internet. Pursuant to a multi-year
agreement, the companies will share in the revenues generated from this
alliance, subject to significant revenue and physician recruitment milestones.
In connection with this strategic alliance, Ventiv has invested $2 million in
RxCentric in exchange for a minority equity position in the firm, which is being
accounted for under the cost method.
Following this transaction, the Company announced the formation of a new
operating unit, e-Ventiv, which will focus on the development of Internet-based
solutions that complement Ventiv's existing sales, communications and strategic
consulting businesses, enhancing the Company's ability to provide superior
outsourced marketing and sales solutions. Specifically, e-Ventiv will focus on
the design and development of solutions oriented toward physician interaction (a
primary objective of the alliance with RxCentric), patient interaction (a
primary objective of the alliance with HeliosHealth.com--see below.) and value-
added information for pharmaceutical clients.
On October 12, 2000, Ventiv entered into a strategic alliance with
HeliosHealth.com ("Helios"), a unique direct-to-consumer ("DTC") Internet
platform that is the leading provider of interactive kiosks - or "e.stations" -
in physician waiting rooms. Helios has installed over 700 e.stations in large,
high prescribing primary care and OB/GYN group practices, which generate more
than 100,000 unique visits per month. In addition, the website generates an
additional 100,000 unique visits per month. Helios has sold over 15 sponsorships
to major pharma companies including Glaxo Wellcome, Johnson & Johnson, Pfizer,
Pharmacia, and SmithKline Beecham. The companies will jointly market targeted
advertising and content to clients and will share revenue generated pursuant to
a multi-year agreement. In addition, Ventiv's HPR division will continue to
integrate DTC into its traditional consulting services and market research
efforts. In connection with this agreement, Ventiv has also made a minority
equity investment in Helios of $0.5 million.
Ventiv does not expect business generated through the alliances with RxCentric
and HeliosHealth.com to materially affect results of operations for the year
ending December 31, 2000.
- 9 -
<PAGE>
Results of Operations
The following sets forth, for the periods indicated, certain components of
Ventiv's income statement data, including such data as a percentage of revenues.
Acquisition and related costs are considered to be non-recurring by Ventiv
because Ventiv's current operations are not expected to incur such costs in
future periods.
<TABLE>
<CAPTION>
($'s in 000's) Three months ended
September 30,
--------------------------------------------------------------------------
2000 1999
---------------------------------- ----------------------------------
<S> <C> <C> <C> <C>
Revenue $103,355 100.0% $ 72,900 100.0%
Cost of services 85,366 82.6% 71,895 97.9%
Selling, general and administrative expenses 10,792 10.4% 13,138 18.7%
Recapitalization costs -- 0.0% 2,100 2.9%
Acquisition and related costs -- 0.0% 5,741 7.9%
Restructuring costs 2,000 1.9% -- 0.0%
-------- ----- -------- ------
Total costs 98,158 95.0% 92,874 127.4%
-------- ----- -------- ------
Income (loss) from operations 5,197 5.0% (19,974) (27.4)%
Interest expense (514) (0.5)% (56) (0.1)%
Interest income 248 0.2% 121 0.2%
-------- ----- -------- ------
Earnings (loss) before income taxes 4,931 4.8% (19,909) (27.3)%
Provision for (benefit from) income taxes (1,972) (1.9)% 6,928 9.5%
-------- ----- -------- ------
Net income (loss) $ 2,959 2.9% $(12,981) (17.8)%
======== ===== ======== ======
Nine months ended
September 30,
--------------------------------------------------------------------------
2000 1999
---------------------------------- ----------------------------------
Revenue $301,257 100.0% $254,159 100.0%
Cost of services 246,741 81.9% 210,040 82.0%
Selling, general and administrative expenses 35,589 11.8% 33,606 13.9%
Recapitalization costs -- 0.0% 2,100 0.8%
Acquisition and related costs -- 0.0% 5,741 2.3%
Restructuring costs 2,000 0.7% 1,694 0.7%
-------- ----- -------- ------
Total costs 284,330 94.4% 253,181 99.6%
-------- ----- -------- ------
Income from operations 16,927 5.6% 978 0.4%
Interest expense (1,565) (0.5)% (179) (0.1)%
Interest income 1,033 0.3% 494 0.2%
-------- ----- -------- ------
Earnings before income taxes 16,395 5.4% 1,293 0.5%
Provision for income taxes (6,558) (2.2)% (1,635) (0.6)%
-------- ----- -------- ------
Net income (loss) $ 9,837 3.3% $ (342) (0.1)%
======== ===== ======== ======
</TABLE>
- 10 -
<PAGE>
Three Months Ended September 30, 2000 Compared to Three Months Ended September
30, 1999
Revenues: Revenues increased by approximately $30.5 million, or 41.8%, to
$103.4 million in the three month period ended September 30, 2000, from $ 72.9
million in the three months ended September 30, 1999.
Revenues in our U.S. Sales group were $59.6 million, an increase of 92.7% over
the $30.9 million in the same period in 1999, and accounted for 57.7% of total
Ventiv revenues for the three months ended September 30, 2000. This growth
primarily resulted from new contracts and expansions of existing business
relationships with Bristol-Myers Squibb, Novo Nordisk and Novartis. The U.S.
Sales group's revenues and operating income for the three months ended September
30, 2000 included approximately $ 1.8 million of incentive fees; there were no
incentive fees recognized in the comparable prior year period.
The U.S. Sales group has seen an increase in demand from clients for
incentive-based and revenue sharing arrangements. Under incentive-based
arrangements, the U.S. Sales group is typically paid a fixed fee and, in
addition, has an opportunity to increase its earnings based on the market
performance of the products being detailed in relation to targeted sales
volumes, sales force performance metrics or a combination thereof. Under revenue
sharing arrangements, the U.S. Sales group's compensation is based on the market
performance of the products being detailed, usually expressed as a percentage of
net sales. The Company expects this trend to continue and, as a result, revenues
derived from these arrangements are expected to increase in the near term in
both absolute and relative terms. These types of arrangements inherently
transfer some market risk from clients to the Company.
In August 1999, the U.S. Sales group entered into a significant multi-year
contract with Bristol-Myers Squibb, Inc. ("BMS"). This contract is scheduled to
transition from a fixed plus incentive fee arrangement to a revenue sharing
arrangement in January 2001, where the payments made to Ventiv will be entirely
determined as a percentage of the revenue stream from the products supported. In
the third quarter of 2000, the Company completed negotiations with BMS, which
converted an anticipated incentive fee for 2000 into an additional fixed fee
payment, payable in December 2000. The Company also commenced discussions with
BMS regarding compensation parameters for 2001 and beyond, the outcome of which
will ultimately determine the U.S. Sales group's future revenue and
profitability under this arrangement. While there can be no assurances as to the
outcome or timing of such agreement, management believes that, in the near
future, it will successfully agree to terms with BMS for 2001 and beyond. Also,
although under certain circumstances the outcome of these dicussions may affect
the timing of recognition of income associated with the additional fixed fee
payment, management expects to recognize the related income in the fourth
quarter of 2000.
The Company's European Sales business generated revenues of $21.8 million, a
decrease of 23.0% from the third quarter of 1999. Revenues generated by the
European businesses represented 21.1 % of total revenues for the fiscal quarter
ended September 30, 2000. The decline in revenue was a result of a combination
of factors, including client losses following the integration of certain
acquired Ventiv businesses, the closure of syndicated sales forces (primarily in
the U.K.) and, to a lesser extent, the impact of foreign exchange rates.
Ventiv Health Communications' revenue represented 15.7% of the Company's third
quarter revenues. Revenues for the group were approximately $16.2 million for
the three months ended September 30, 2000 which represented an increase of $8.0
million from the $8.2 million of revenue recorded in 1999. This increase was
attributable to the shift of business focus away from print media toward live
events, beginning in the third quarter of 1999. Live events (meetings;
teleconferences; symposia, etc.) are typically large-scale engagements with
higher contract values. In addition, margins on such engagements are typically
lower than those earned on print media business, which require a higher degree
of specialized effort. As a result, revenues shifted from third quarter of 1999
to later periods.
Health Products Research generated 5.6 % of total revenues, and $5.8 million
and $5.4 million in the three-month periods ended September 30, 2000 and 1999,
respectively. Revenues increased $0.4 million or 7.0%, from the third quarter in
1999. The increase in revenues was primarily a result of an expansion of the
group's client base, partially offset by the effects of consolidation in the
pharmaceutical industry. Such consolidation created additional demand for
certain services in the third quarter of fiscal 1999 and did not recur in 2000.
- 11 -
<PAGE>
Costs of Services: Costs of services increased by approximately $13.5 million,
or 18.7%, to $85.4 million this fiscal quarter from $71.9 million in the three-
month period ending September 30, 1999. Costs of services decreased as a
percentage of revenues to 82.6% from 97.9% in the three -month periods ended
September 30, 2000 and 1999, respectively. The decrease in costs of services as
a percentage of revenues was primarily due to a substantial increase in the
profitability of the U.S. Sales group, led in large part by margins derived from
the BMS contract. The decrease was also partly attributable to: i) the results
of previous actions taken in the UK relating to reductions of syndicated sales
force capacity; ii) the effect of one-time start-up costs of approximately $2.0
million in 1999 related to the BMS contract, and iii) the effect of incentive
fee payments for the three-month period ending September 30, 2000 of $1.8
million, for which there were no corresponding costs of services.
Selling, General and Administrative Expenses: Selling, general and
administrative expenses decreased by approximately $2.9 million, or 17.9%, to
$10.8 million from $13.1 million in the three-month periods ending September 30,
2000 and 1999, respectively. Selling, general and administrative expenses
decreased as a percentage of revenue to 10.4% for the three months ending
September 30, 2000 from 18.7% for the three months ending September 30, 1999.
The decline as a percentage of revenue is primarily the result of the effect of
measures taken in the fourth quarter of 1999 and during the third quarter of
2000 to restructure the European operations. Savings were realized at the
corporate level following the completion of the transition of the accounting and
finance functions from Snyder, eliminating the assistance fees charged
previously for such services. In addition, the decrease in selling, general and
administrative costs reflects the benefit of actions taken earlier this fiscal
year to reduce overall operating costs at Ventiv Health Communications. These
savings were partially offset by an increase in infrastructure costs and
investments related to e-Ventiv and other new business development initiatives.
Recapitalization Costs: During the three-month period ending September 30,
1999, Ventiv recorded $2.1 million of recapitalization costs in connection with
the spin-off from Snyder. This cost consisted of non-cash charges related to
restricted stock, issued to certain key employees of Ventiv, which partially
vested immediately following the Distribution. There was no similar charge in
2000.
Acquisition and Related Costs: During the three months ended September 30,
1999, the Company recorded $5.7 million in non-recurring acquisition and related
costs with regard to a payment made by Ventiv, in the form of 695,304 shares of
Ventiv common stock, to the prior owners of PromoTech Research Associates Inc.
("PromoTech"), in exchange for the release of any and all claims against Snyder
or Ventiv, related to the purchase of PromoTech. The payment was not provided
for in the purchase agreement and is not a part of the purchase price for
accounting purposes. There were no similar costs in 2000.
Restructuring Costs: During the third quarter of 2000, management completed an
evaluation of staffing levels and infrastructure of its European operations.
Following this evaluation, management adopted a restructuring plan which
provided for: i) rationalization of senior and mid-level management in France,
the United Kingdom and Austria; ii) early termination of leases in France and
Austria to reduce overall facilities costs and consolidate certain sales
operations, respectively, and; iii) the disposition of assets not associated
with Ventiv's core businesses. The Company will continue to do business in
Austria, but these activities will now be managed by the German operation. In
connection with the adoption of this plan, the Company recorded a pre-tax charge
of $2.0 million.
Interest Expense: Ventiv recorded $0.5 million of interest expense in the
three months ended September 30, 2000, a notable increase over the relatively
immaterial amount recorded in the comparable prior year period. Interest expense
increased as a direct result of net borrowings drawn against the Company's
revolving line of credit, in support of operations, investing activities and in
connection with the Company's share repurchase program (see "Liquidity and
Capital Resources").
Investment Income: Ventiv recorded approximately $0.2 million and $0.1 million
of investment income in the three months ended September 30, 2000 and 1999,
respectively. The increase in interest income reflects the benefits from
management's efforts to centralize treasury functions for its U.S. operations
allowing for more timely and effective concentration and investment of cash
balances. Variations in future investment income will result from differences in
average amounts of cash and cash equivalents available for investment and the
prevailing short-term interest rates during these periods.
Provision for (Benefit from) Income Taxes: Ventiv recorded a provision for
income taxes using an estimated effective tax rate
- 12 -
<PAGE>
of 40.0% for the three-month period ended September 30, 2000, and a benefit
using an effective tax rate of 34.8% for the three-month period ended September
30, 1999. Ventiv's current effective tax rate reflects the full impact of
non-deductible goodwill amortization associated with prior acquisitions and was
based on current internal earnings projections for the year ending December 31,
2000 by tax jurisdiction.
Net Earnings and Earnings Per Share ("EPS"): Ventiv's net earnings increased
by approximately $16 million to $3.0 million, from a loss of $ 13.0 million, in
the three months ended September 30, 2000 and 1999, respectively. Higher revenue
and reduced spending levels, coupled with the absence of certain non-recurring
acquisition and related costs, contributed to the increase in net earnings, as
more fully explained above.
Shares used in computing basic and diluted EPS decreased by approximately 1.4
million and 0.4 million shares, respectively, due to the impact of the Company's
share repurchase program. The impact of share repurchases on shares used in
computing diluted EPS was offset in part by the inclusion of common stock
equivalents relating to employee stock options and restricted stock awards.
These items were not included in pro forma diluted EPS for the three months
ended September 30, 1999, as they were anti-dilutive to the net loss per share
and were not issued until the date of the Distribution (see Part I.--Item 1.--
Notes to Condensed Consolidated Financial Statements--Note 3 "Share Repurchase
Program" and Note 4 "Earnings per Share").
Nine months Ended September 30, 2000 Compared to Nine months Ended September 30,
1999
Revenues: Revenues increased by approximately $47.1 million, or 18.5%, to
$301.3 million in the nine-month period ended September 30, 2000, from $254.2
million in the nine-month period ended September 30, 1999.
Revenues in our U.S. Sales group were $169.1 million, an increase of 80%, or
$75.2 million, over 1999, and accounted for 56.1% of total Ventiv revenues for
the nine months ended September 30, 2000. This growth primarily resulted from
new contracts and expansions of existing business relationships with Bristol-
Myers Squibb, Forest Labs, Johnson & Johnson and Novartis. The U.S. Sales
group's revenues and operating income for the nine months ended September 30,
2000 included approximately $4.4 million of incentive fees; there were no
incentive fees recognized in the comparable prior year period.
The Company's European Sales business generated revenues of $69.1 million, a
decrease of 32.3% from 1999. Revenues generated by the European businesses
represented 22.9% of total revenues for the nine-month period ended September
30, 2000. The decline in revenue was a result of a combination of factors,
including client losses following the integration of certain acquired Ventiv
businesses, the closure of syndicated sales forces (primarily in the U.K.) and,
to a lesser extent, the impact of foreign exchange rates.
Ventiv Health Communications' revenue represented 15.0% of the Company's total
revenues. Revenues for the group were approximately $45.2 million for the nine
months ended September 30, 2000 which represents an increase of $3.4 million or
8.2% from the $41.8 million of revenue recorded in 1999. This increase was
attributable to the shift of business focus away from print media toward live
events, beginning in the third quarter of 1999. Live events (meetings;
teleconferences; symposia, etc.) are typically large-scale engagements with
higher contract values. In addition, margins on such engagements are typically
lower than those earned on print media business, which require a higher degree
of specialized effort. As a result, revenues shifted from the third quarter of
1999 to later periods.
Health Products Research generated 5.9% of total revenues for the nine-month
period ended September 30, 2000. Revenues increased $1.5 million or 9.0%, from
$17.8 million to $16.3 million in the nine-month periods ended September 30,
2000 and 1999, respectively. The increase in revenues was primarily a result of
an expansion of the group's client base, partially offset by the effects of
consolidation in the pharmaceutical industry. Such consolidation created
additional demand for certain services in the second and third quarters of
fiscal 1999 and did not recur in 2000.
Costs of Services: Costs of services increased by approximately $10.4 million,
or 17.5%, to $246.7 million for the nine-month period ended September 30, 2000
from $210.0 million in the nine-month period ending September 30, 1999. Costs of
services increased by approximately 1% less than the growth in revenues. Costs
of services remained relatively constant as a percentage of revenue at
approximately 82.0%. However, the costs of services for the nine months ended
September 30, 2000 were adversely impacted by approximately $2.0 million of one-
time charges, which were recorded as part of ongoing operations during the first
quarter. These charges related primarily to a reduction in syndicated sales
force capacity in the U.K.-based contract
- 13 -
<PAGE>
sales business and to efforts to reduce headcount and other fixed costs in
Ventiv Health Communications. The effect of these charges was partially offset
by higher margins from the U.S. Contract Sales business, which included profits
contributed by the BMS contract. The cost of services for 1999 were affected in
the third quarter by the one-time costs incurred with respect to the start-up of
the BMS contract. We believe that the actions taken this year and late in 1999,
including the reduction of syndicated sales force capacity in the U.K., will
continue to benefit future periods.
Selling, General and Administrative Expenses: Selling, general and
administrative expenses increased by approximately $2.0 million, or 5.9%, to
$35.6 million from $33.6 million in the nine-month periods ended September 30,
2000 and 1999, respectively. Selling, general, and administrative expenses as a
percentage of revenues decreased to 11.8% from 13.9%. The increase in selling,
general and administrative expenses was due largely to additional ongoing
overhead expenses, beginning in the third quarter of 1999, related to the
formation of Ventiv's independent management and administrative infrastructure
following the Distribution. In addition, the increase also reflects the
Company's investments related to e-Ventiv and other new business development
initiatives.
Recapitalization Costs: During the three-month period ending September 30,
1999, Ventiv recorded $2.1 million of recapitalization costs in connection with
the spin-off from Snyder Communications Inc. ("Snyder"). This cost consisted of
non-cash charges related to restricted stock, issued to certain key employees of
Ventiv, which partially vested immediately following the Distribution. There was
no similar charge in 2000.
Acquisition and Related Costs: During the three months ended September 30,
1999, the Company recorded $5.7 million in non-recurring acquisition and related
costs with regard to a payment made by Ventiv, in the form of 695,304 shares of
Ventiv common stock, to the prior owners of PromoTech, in exchange for the
release of any and all claims against Snyder or Ventiv, related to the purchase
of PromoTech. The payment was not provided for in the purchase agreement and is
not a part of the purchase price for accounting purposes. There were no similar
costs in 2000.
Restructuring Costs: During the third quarter of 2000, management completed an
evaluation of staffing levels and infrastructure of its European operations.
Following this evaluation, management adopted a restructuring plan which
provided for: i) rationalization of senior and mid-level management in France,
the United Kingdom and Austria; ii) early termination of leases in France and
Austria to reduce overall facilities costs and consolidate certain sales
operations, respectively, and; iii) the disposition of assets not associated
with Ventiv's core businesses. The Company will continue to do business in
Austria, but these activities will now be managed by the German operation. In
connection with the adoption of this plan, the Company recorded a pre-tax charge
of $2.0 million.
Non-recurring costs recorded in the nine-month period ended September 30,1999
included charges of $1.7 million related to the consolidation and integration of
certain of Ventiv's acquired operations within U.S. Contract Sales, Ventiv
Health Communications and the Company's U.K.-based sales business.
The Company believes that actions taken will substantially benefit future
operations.
Interest Expense: Ventiv recorded $1.6 million of interest expense in the nine
months ended September 30, 2000, a notable increase over the $0.2 million
recorded in 1999. Interest expense increased as a direct result of net
borrowings drawn against the Company's revolving line of credit, in support of
operations, investing activities and in connection with the Company's share
repurchase program (see "Liquidity and Capital Resources").
Investment Income: Ventiv recorded approximately $1.0 million and $0.5 million
of investment income in the nine months ended September 30, 2000 and 1999,
respectively. The increase in interest income reflects the benefits from
management's efforts to centralize treasury functions for its U.S. operations
allowing for more timely and effective concentration and investment of cash
balances. Variations in future investment income will result from differences in
average amounts of cash and cash equivalents available for investment and the
prevailing short-term interest rates during these periods.
Provision for Income Taxes: Ventiv recorded provisions for income taxes using
an estimated effective tax rate of 40% for the nine-month period ended September
30, 2000. Ventiv's current effective tax rate reflects the full impact of non-
deductible goodwill amortization associated with prior acquisitions and was
based on current internal earnings projections for the year ending December 31,
2000 by tax jurisdiction. For the nine-months ended September 30,
- 14 -
<PAGE>
1999, the Company used an effective rate of 127% and recorded a tax provision on
a net book loss due to the non-deductibility of certain goodwill amortization
and other acquisition and related, non-recurring costs.
Net Earnings and Earnings Per Share ("EPS"): Ventiv's net earnings increased
by $10.1 million to $9.8 million, from a loss of $0.3 million, in the nine-month
periods ended September 30, 2000 and 1999, respectively, as more fully explained
above.
Shares used in computing basic and diluted EPS decreased by approximately 1.0
million and 0.3 million shares, respectively, due to the impact of the Company's
share repurchase program. The impact of share repurchases on shares used in
computing diluted EPS was offset in part by the inclusion of common stock
equivalents relating to employee stock options and restricted stock awards.
These items were not included in pro forma diluted EPS for the nine months ended
September 30, 1999, as they were anti-dilutive to the net loss per share and
were not issued until the date of the Distribution (see Part I.--Item 1.--Notes
to Condensed Consolidated Financial Statements--Note 3 "Share Repurchase
Program" and Note 4 "Earnings Per Share").
Liquidity and Capital Resources
At September 30, 2000, Ventiv had $26.7 million of cash and cash equivalents,
a decrease of $11.0 million from December 31, 1999. For the nine-month periods
ending September 30, 2000 compared to September 30, 1999, cash used in
operations increased by $4.8 million and cash used in investing activities
increased by $0.2 million. In addition, cash provided by financing activities
decreased by $20.1 million to $0.2 million. Cash provided by financing
activities in the nine months ended September 30, 1999 included approximately
$22.6 million of funds provided by Snyder prior to the Distribution date (see
below). These decreases were partially offset by favorable effects of changes in
foreign exchange rates.
Cash used by operations was $6.0 million in 2000 compared to $1.2 million in
1999. This increase was primarily due to the combined effect of increased
accounts receivable, resulting from the growth of businesses, decreased amounts
of unearned revenue, resulting from the delivery of services on longer term
contracts for which advances had been received in late 1999 and early 2000, and
income tax payments made on behalf of the U.S. operating businesses. These
decreases were partially offset by the increase in net income and depreciation
expense. During the nine months ended September 30, 2000, the US Sales group
entered into a master lease agreement for a fleet of automobiles valued at $17.3
million. This resulted in an increase of approximately $2 million in
depreciation expense related to these leased automobiles.
Cash used by investing activities was $5.8 million and $5.6 million through
September 30, 2000 and 1999, respectively. Cash expenditures in 2000 relate to
the investment made in RxCentric and capital expenditures. In 1999, investing
activities included $2.9 million of cash acquired through the purchase of a
subsidiary.
Cash financing activities was $0.2 million and $20.3 million for the nine
months ended September 30, 2000 and 1999, respectively. During 2000, the Company
made net borrowings under the line of credit of $19.0 million (of which $16.0
million has been classified as non-current) and repaid $1.2 million against a
previously outstanding foreign line of credit. During the nine months ended
September 30, 2000, the Company made payments on capital lease obligations
totalling approximately $1.7 million (see above). During 1999, the Company
received investments and advances from Snyder of approximately $22.6 million
related to the forgiveness of the amounts owed to Snyder as part of the
Distribution transaction which occured on September 27, 1999. In addition, under
the stock repurchase plan, in 2000 the Company has acquired and retired
approximately 1.7 million shares of common stock for approximately $17.4 million
(including applicable fees and brokers' commissions).
On December 1, 1999, we entered into a $50 million unsecured revolving credit
facility, expiring with a term of four years. Borrowings may be used for general
corporate purposes, acquisitions and the repurchase of up to $37.5 million of
Ventiv Health, Inc. common stock. Interest on amounts borrowed under the credit
facility is based on the London Interbank Offered Rate ("LIBOR") or the lending
bank's base rate of interest. Availability under this credit facility is subject
to our compliance with various financial ratios, operating covenants and other
customary conditions. At September 30, 2000, the Company was in compliance with
these financial covenants.
We believe our cash and equivalents, as well as cash provided by operations,
will be sufficient to fund our current operations and planned capital
expenditures over the next 12 months and for the foreseeable future. We plan to
focus on internal growth in the near term as the primary means of our expansion,
although we will consider
- 15 -
<PAGE>
attractive acquisition opportunities as they arise. Cash provided from
operations may not be sufficient to fund internal growth initiatives which we
may pursue. If we pursue significant internal growth initiatives or if we
acquire additional businesses in transactions that include any cash payment as
part of the purchase price, both in the short-term and the long-term, we will
first use excess cash available from operations and then pursue additional debt
or equity financing as sources of cash necessary to complete any acquisitions.
In addition to borrowing under our line of credit, we could pursue additional
debt or equity transactions to finance acquisitions, depending on market
conditions. We cannot assure you that we will be successful in raising the cash
required to complete all acquisition opportunities which we may wish to pursue
in the future.
We are subject to the impact of foreign currency fluctuations, specifically
that of the British pound, the German mark and the French franc. To date,
changes in the exchange rates of the British pound, the German mark and the
French franc have not had a material impact on our liquidity or results of
operations. We continually evaluate our exposure to exchange rate risk but do
not currently hedge such risk. We do not expect the introduction of the Euro to
have a material impact on our operations or cash flows in the near term. We will
continue to evaluate the impact of the introduction of the Euro as we continue
to expand our services in Europe.
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk
The Company is exposed to market risk from changes in market interest rates
and foreign currency exchange rates. We are subject to interest rate risk on our
debt for changes in the LIBOR rates, and we are also subject to foreign currency
exchange rate risk with respect to our international operations. We do not
currently engage in hedging or other market risk management tools.
Long-term Debt Exposure
As of September 30, 2000, the Company has drawn $19 million against its $50.0
million unsecured revolving credit facility. Based upon the amount outstanding,
if the LIBOR rate were to increase by 1%, Ventiv would incur an additional $0.2
million of interest expense on an annual basis.
Foreign Currency Exchange Rate Exposure
Fluctuations in foreign currency exchange rates affect the reported amounts of
our assets, liabilities and operations. For purposes of quantifying the risk
associated with fluctuations in the foreign exchange rate, we assumed a
hypothetical 10% detrimental change in the exchange rates on our assets,
liabilities and revenue denominated in foreign currencies. A 10% fluctuation was
assumed for all exchange rates at September 30, 2000. The Company's material
exposures to foreign exchange rate fluctuations relate to the French Franc, the
British Pound, and the German Mark. Approximately 43%, 28% and 29% of the
Company's foreign-sourced revenues for the nine-month period ended September 30,
2000 were generated by operating units based in France, the United Kingdom and
Germany, respectively. The table below presents the hypothetical impact of an
assumed 10% unfavorable change in all exchange rates to which we are exposed on
total assets, liabilities and revenues.
<TABLE>
<CAPTION>
10% Decrease in
---------------
Balance at Value of Local
--------- --------------
September 30 Currencies to
------------ -------------
2000 US Dollar
---- ---------
<S> <C> <C>
Total Assets.................................................. $241,721 $235,735
Total Liabilities............................................. 102,763 95,773
Revenues...................................................... 301,257 294,345
</TABLE>
- 16 -
<PAGE>
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings
The Company is subject to various proceedings arising in the normal course of
business, none of which individually or in the aggregate, is expected to have a
material adverse effect on the Company's financial condition results of
operations or liquidity.
ITEM 4. Submission of Matters to a Vote of Security Holders
Not applicable
ITEM 6. Exhibits and Reports on Form 8-K
(a) Exhibits
27.1 Financial Data Schedule
(b) Reports on Form 8-K
None
- 17 -
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
VENTIV HEALTH, INC.
By: /s/ Gregory S. Patrick
Date: November 7, 2000
Gregory S. Patrick
Chief Financial Officer
(Principal Financial Officer)
By: /s/ Joseph S. Durko
Joseph S. Durko
Vice President and Controller
(Principal Accounting Officer)
- 18 -
